Does the media refer more to RYTM or SEPN?

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 9 mentions for Septerna. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Septerna's score of 1.13 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SEPN or TGTX?

TG Therapeutics has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $98.88M 18.37 -$48.88M -$0.54 N/A TG Therapeutics $799.54M 10.32 $447.18M $2.74 19.68

Does the media favor SEPN or TGTX?

In the previous week, Septerna had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for Septerna and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Septerna's score of 1.13 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SEPN or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 12 mentions for Oruka Therapeutics and 9 mentions for Septerna. Oruka Therapeutics' average media sentiment score of 1.45 beat Septerna's score of 1.13 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, CGON or SEPN?

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $6.23M 1,058.04 -$160.99M -$2.69 N/A Septerna $98.88M 18.37 -$48.88M -$0.54 N/A

Is CGON or SEPN more profitable?

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Septerna -24.51% -9.57% -6.28%

Does the media prefer CGON or SEPN?

In the previous week, Septerna had 3 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Septerna and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.55 beat Septerna's score of 1.13 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SEPN or SRRK?

Septerna has higher revenue and earnings than Scholar Rock. Septerna is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $98.88M 18.37 -$48.88M -$0.54 N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is SEPN or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% Scholar Rock N/A -160.19% -87.18%

Does the media favor SEPN or SRRK?

In the previous week, Scholar Rock had 1 more articles in the media than Septerna. MarketBeat recorded 10 mentions for Scholar Rock and 9 mentions for Septerna. Scholar Rock's average media sentiment score of 1.49 beat Septerna's score of 1.13 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Septerna (SEPN) Competitors

$38.91 -1.56 (-3.85%)

As of 08/28/2026 04:00 PM Eastern

Compare

SEPN vs. RYTM, TGTX, ORKA, CGON, and SRRK

Should you buy Septerna stock or one of its competitors? Septerna's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Oruka Therapeutics (ORKA), CG Oncology (CGON), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Septerna compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Septerna has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 9 mentions for Septerna. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Septerna's score of 1.13 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a net margin of -24.51% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Septerna's return on equity of -9.57% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Septerna	-24.51%	-9.57%	-6.28%

Rhythm Pharmaceuticals currently has a consensus price target of $141.12, suggesting a potential upside of 31.68%. Septerna has a consensus price target of $52.44, suggesting a potential upside of 34.78%. Given Septerna's stronger consensus rating and higher possible upside, analysts plainly believe Septerna is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Septerna beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Septerna compare to TG Therapeutics?

Septerna (NASDAQ:SEPN) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Septerna had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for Septerna and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Septerna's score of 1.13 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Septerna's net margin of -24.51%. TG Therapeutics' return on equity of 73.49% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
TG Therapeutics	55.22%	73.49%	34.14%

Septerna presently has a consensus price target of $52.44, suggesting a potential upside of 34.78%. TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 16.82%. Given Septerna's stronger consensus rating and higher probable upside, research analysts clearly believe Septerna is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

58.6% of TG Therapeutics shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68

Summary

TG Therapeutics beats Septerna on 10 of the 17 factors compared between the two stocks.

How does Septerna compare to Oruka Therapeutics?

Septerna (NASDAQ:SEPN) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Septerna presently has a consensus price target of $52.44, indicating a potential upside of 34.78%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 47.36%. Given Oruka Therapeutics' higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 12 mentions for Oruka Therapeutics and 9 mentions for Septerna. Oruka Therapeutics' average media sentiment score of 1.45 beat Septerna's score of 1.13 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Septerna has higher revenue and earnings than Oruka Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Oruka Therapeutics beats Septerna on 8 of the 15 factors compared between the two stocks.

How does Septerna compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Septerna had 3 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Septerna and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.55 beat Septerna's score of 1.13 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,058.04	-$160.99M	-$2.69	N/A
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Septerna	-24.51%	-9.57%	-6.28%

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

CG Oncology presently has a consensus target price of $83.18, indicating a potential upside of 11.89%. Septerna has a consensus target price of $52.44, indicating a potential upside of 34.78%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Septerna beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Septerna compare to Scholar Rock?

Septerna (NASDAQ:SEPN) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Septerna has higher revenue and earnings than Scholar Rock. Septerna is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Septerna presently has a consensus price target of $52.44, indicating a potential upside of 34.78%. Scholar Rock has a consensus price target of $58.77, indicating a potential upside of 1.68%. Given Septerna's higher probable upside, research analysts plainly believe Septerna is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, Scholar Rock had 1 more articles in the media than Septerna. MarketBeat recorded 10 mentions for Scholar Rock and 9 mentions for Septerna. Scholar Rock's average media sentiment score of 1.49 beat Septerna's score of 1.13 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Scholar Rock beats Septerna on 9 of the 16 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-72.06	11.62	273.16	25.45
Price / Sales	18.37	1,291.80	604.48	76.58
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.69	16.53	12.98	6.14
Net Income	-$48.88M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-2.73%	-0.31%	0.13%	-0.80%
1 Month Performance	10.60%	9.80%	7.08%	4.13%
1 Year Performance	221.57%	55.66%	24.67%	15.17%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	3.3748 of 5 stars	$38.91 -3.9%	$52.44 +34.8%	+221.6%	$1.82B	$98.88M	N/A	N/A	Positive News
RYTM Rhythm Pharmaceuticals	2.8757 of 5 stars	$115.25 -0.2%	$142.44 +23.6%	+3.9%	$7.90B	$239.92M	N/A	140	Positive News Analyst Forecast Gap Down
TGTX TG Therapeutics	3.4384 of 5 stars	$50.26 +2.0%	$63.00 +25.3%	+83.9%	$7.69B	$799.54M	18.34	290	Positive News
ORKA Oruka Therapeutics	2.8888 of 5 stars	$113.08 +0.4%	$134.30 +18.8%	+515.8%	$7.49B	N/A	N/A	N/A	News Coverage Positive News
CGON CG Oncology	3.2698 of 5 stars	$76.29 -1.1%	$83.18 +9.0%	+177.2%	$6.76B	$6.23M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. RYTM, TGTX, ORKA, CGON, and SRRK

How does Septerna compare to Rhythm Pharmaceuticals?

Summary

How does Septerna compare to TG Therapeutics?

Summary

How does Septerna compare to Oruka Therapeutics?

Summary

How does Septerna compare to CG Oncology?

Summary

How does Septerna compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. RYTM, TGTX, ORKA, CGON, and SRRK

How does Septerna compare to Rhythm Pharmaceuticals?

Which has higher earnings & valuation, RYTM or SEPN?

Which has more volatility & risk, RYTM or SEPN?

Does the media refer more to RYTM or SEPN?

Is RYTM or SEPN more profitable?

Do analysts prefer RYTM or SEPN?

Summary

How does Septerna compare to TG Therapeutics?

Does the media favor SEPN or TGTX?

Is SEPN or TGTX more profitable?

Do analysts prefer SEPN or TGTX?

Which has more volatility & risk, SEPN or TGTX?

Do insiders and institutionals have more ownership in SEPN or TGTX?

Which has preferable earnings and valuation, SEPN or TGTX?

Summary

How does Septerna compare to Oruka Therapeutics?

Do analysts prefer SEPN or ORKA?

Which has more volatility and risk, SEPN or ORKA?

Do insiders & institutionals hold more shares of SEPN or ORKA?

Does the media refer more to SEPN or ORKA?

Is SEPN or ORKA more profitable?

Which has stronger valuation & earnings, SEPN or ORKA?

Summary

How does Septerna compare to CG Oncology?

Does the media prefer CGON or SEPN?

Do institutionals and insiders believe in CGON or SEPN?

Which has better valuation and earnings, CGON or SEPN?

Is CGON or SEPN more profitable?

Which has more volatility & risk, CGON or SEPN?

Do analysts recommend CGON or SEPN?

Summary

How does Septerna compare to Scholar Rock?

Which has higher valuation & earnings, SEPN or SRRK?

Which has more risk & volatility, SEPN or SRRK?

Do institutionals and insiders believe in SEPN or SRRK?

Do analysts prefer SEPN or SRRK?

Does the media favor SEPN or SRRK?

Is SEPN or SRRK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools